380 related articles for article (PubMed ID: 22538053)
1. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
2. Active targeting behaviors of biotinylated pluronic/poly(lactic acid) nanoparticles in vitro through three-step biotin-avidin interaction.
Xiong XY; Gong YC; Li ZL; Li YP; Guo L
J Biomater Sci Polym Ed; 2011; 22(12):1607-19. PubMed ID: 20699057
[TBL] [Abstract][Full Text] [Related]
3. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
Pulkkinen M; Pikkarainen J; Wirth T; Tarvainen T; Haapa-aho V; Korhonen H; Seppälä J; Järvinen K
Eur J Pharm Biopharm; 2008 Sep; 70(1):66-74. PubMed ID: 18555675
[TBL] [Abstract][Full Text] [Related]
4. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
5. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
6. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
7. Graphene oxide stabilized by PLA-PEG copolymers for the controlled delivery of paclitaxel.
Angelopoulou A; Voulgari E; Diamanti EK; Gournis D; Avgoustakis K
Eur J Pharm Biopharm; 2015 Jun; 93():18-26. PubMed ID: 25817600
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-loaded polymeric nanoparticles based on PCL-PEG-PCL: preparation, in vitro and in vivo evaluation.
Zhang L; He Y; Yu M; Song C
J Control Release; 2011 Nov; 152 Suppl 1():e114-6. PubMed ID: 22195789
[No Abstract] [Full Text] [Related]
9. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
10. Transferrin/folate dual-targeting Pluronic F127/poly(lactic acid) polymersomes for effective anticancer drug delivery.
Wang QX; Chen X; Li ZL; Gong YC; Xiong XY
J Biomater Sci Polym Ed; 2022 Jun; 33(9):1140-1156. PubMed ID: 35179085
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy.
Oh KS; Song JY; Cho SH; Lee BS; Kim SY; Kim K; Jeon H; Kwon IC; Yuk SH
J Control Release; 2010 Dec; 148(3):344-50. PubMed ID: 20797418
[TBL] [Abstract][Full Text] [Related]
12. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel delivery.
Song N; Liu W; Tu Q; Liu R; Zhang Y; Wang J
Colloids Surf B Biointerfaces; 2011 Oct; 87(2):454-63. PubMed ID: 21719259
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery and intraoperative administration of paclitaxel-loaded expansile nanoparticles delay tumor recurrence in ovarian carcinoma.
Gilmore D; Schulz M; Liu R; Zubris KA; Padera RF; Catalano PJ; Grinstaff MW; Colson YL
Ann Surg Oncol; 2013 May; 20(5):1684-93. PubMed ID: 23128939
[TBL] [Abstract][Full Text] [Related]
15. Vesicles from Pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery.
Xiong XY; Li YP; Li ZL; Zhou CL; Tam KC; Liu ZY; Xie GX
J Control Release; 2007 Jul; 120(1-2):11-7. PubMed ID: 17509718
[TBL] [Abstract][Full Text] [Related]
16. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
17. The targeting properties of folate-conjugated Pluronic F127/poly (lactic-co-glycolic) nanoparticles.
Luo YY; Xiong XY; Cheng F; Gong YC; Li ZL; Li YP
Int J Biol Macromol; 2017 Dec; 105(Pt 1):711-719. PubMed ID: 28716749
[TBL] [Abstract][Full Text] [Related]
18. Development of disulfide core-crosslinked pluronic nanoparticles as an effective anticancer-drug-delivery system.
Abdullah-Al-Nahain ; Lee H; Lee YS; Lee KD; Park SY
Macromol Biosci; 2011 Sep; 11(9):1264-71. PubMed ID: 21717576
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
20. Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.
Zhang X; Chen J; Kang Y; Hong S; Zheng Y; Sun H; Xu C
Int J Pharm; 2013 Sep; 453(2):498-505. PubMed ID: 23811008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
